SeaStar Medical Holding Corporation (NASDAQ:ICU) Short Interest Update

SeaStar Medical Holding Corporation (NASDAQ:ICU) saw a large increase in short interest in July. As of July 15th, there was short interest totaling 138,925 shares, an increase of 69.6% from the June 30th total of 81,907 shares. Based on an average daily trading volume, of 149,755 shares, the days-to-cover ratio is presently 0.9 days. Currently, 3.5% of the company’s stock are short sold.

Institutional Trading of SeaStar Medical

A number of institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd grew its stake in SeaStar Medical by 395.4% in the 2nd quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after buying an additional 48,674 shares during the last quarter. Millennium Management LLC bought a new position in SeaStar Medical in the 3rd quarter worth $102,000. Finally, Jane Street Group LLC acquired a new position in SeaStar Medical during the 4th quarter worth $30,000. 1.69% of the stock is currently owned by institutional investors and hedge funds.

SeaStar Medical Stock Performance

Shares of ICU stock opened at $3.18 on Friday. The stock’s 50 day simple moving average is $3.71 and its 200 day simple moving average is $3.36. SeaStar Medical has a twelve month low of $2.07 and a twelve month high of $12.50. The company has a market capitalization of $12.72 million, a price-to-earnings ratio of -0.66 and a beta of -1.05.

SeaStar Medical (NASDAQ:ICU) last posted its earnings results on Wednesday, May 13th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08). The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.44 million. SeaStar Medical had a negative return on equity of 146.29% and a negative net margin of 828.62%. On average, analysts forecast that SeaStar Medical will post -3.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Maxim Group set a $8.00 price target on shares of SeaStar Medical and gave the company a “buy” rating in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of SeaStar Medical in a research note on Friday, July 17th. Finally, Wall Street Zen lowered shares of SeaStar Medical from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, SeaStar Medical presently has a consensus rating of “Hold” and a consensus price target of $8.00.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.